These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 33972360)

  • 1. Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases.
    Gulsin GS; Graham-Brown MPM; Squire IB; Davies MJ; McCann GP
    Heart; 2022 Jan; 108(1):16-21. PubMed ID: 33972360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose-response meta-analysis involving 10 randomized clinical trials and 71 553 individuals.
    Lin DS; Yu AL; Lo HY; Lien CW; Lee JK; Chiang FT; Tu YK
    Eur J Endocrinol; 2023 Jul; 189(1):S17-S25. PubMed ID: 37474112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
    Patel SM; Kang YM; Im K; Neuen BL; Anker SD; Bhatt DL; Butler J; Cherney DZI; Claggett BL; Fletcher RA; Herrington WG; Inzucchi SE; Jardine MJ; Mahaffey KW; McGuire DK; McMurray JJV; Neal B; Packer M; Perkovic V; Solomon SD; Staplin N; Vaduganathan M; Wanner C; Wheeler DC; Zannad F; Zhao Y; Heerspink HJL; Sabatine MS; Wiviott SD
    Circulation; 2024 Jun; 149(23):1789-1801. PubMed ID: 38583093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles for SGLT2 Inhibitors in Cardiorenal Disease.
    Green JB; McCullough PA
    Cardiorenal Med; 2022; 12(3):81-93. PubMed ID: 35835083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of sodium-glucose cotransporter 2 inhibitors with risk of major adverse cardiovascular events in type 2 diabetes patients with acute coronary syndrome: a propensity score‑matched analysis.
    Liu T; Fan Z; Xiao B; He C; Wang S
    Cardiovasc Diabetol; 2024 Mar; 23(1):106. PubMed ID: 38528542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Furtado RHM; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Lancet; 2019 Jan; 393(10166):31-39. PubMed ID: 30424892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium-Glucose Cotransporter 2 Inhibitors.
    Verma S; Mudaliar S; Greasley PJ
    Adv Ther; 2024 Jan; 41(1):92-112. PubMed ID: 37943443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now.
    Johansen ME; Argyropoulos C
    Clin Cardiol; 2020 Dec; 43(12):1376-1387. PubMed ID: 33165977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials.
    Singh AK; Singh A; Singh R
    Endocr Pract; 2023 Jul; 29(7):509-516. PubMed ID: 37037286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
    Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
    Am Heart J; 2021 Feb; 232():10-22. PubMed ID: 33214130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restricted Mean Survival Time Analysis to Estimate SGLT2i-Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan.
    Peng ZY; Yang CT; Kuo S; Wu CH; Lin WH; Ou HT
    JAMA Netw Open; 2022 Dec; 5(12):e2246928. PubMed ID: 36520437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolution of type 2 diabetes management: glycemic control and beyond with SGLT-2 inhibitors and GLP-1 receptor agonists.
    Serowik TC; Pantalone KM
    J Osteopath Med; 2024 Mar; 124(3):127-135. PubMed ID: 37921061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
    Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
    Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
    Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
    Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia.
    Real J; Vlacho B; Ortega E; Vallés JA; Mata-Cases M; Castelblanco E; Wittbrodt ET; Fenici P; Kosiborod M; Mauricio D; Franch-Nadal J
    Cardiovasc Diabetol; 2021 Jul; 20(1):139. PubMed ID: 34243779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults.
    Mancini GBJ; O'Meara E; Zieroth S; Bernier M; Cheng AYY; Cherney DZI; Connelly KA; Ezekowitz J; Goldenberg RM; Leiter LA; Nesrallah G; Paty BW; Piché ME; Senior P; Sharma A; Verma S; Woo V; Darras P; Grégoire J; Lonn E; Stone JA; Yale JF; Yeung C; Zimmerman D
    Can J Cardiol; 2022 Aug; 38(8):1153-1167. PubMed ID: 35961754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
    Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
    Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of sodium-glucose cotransporter 2 inhibitors in cardiovascular disease.
    Khater J; Malakouti S; Khoury AE; Cortese B
    J Cardiovasc Med (Hagerstown); 2024 Apr; 25(4):247-258. PubMed ID: 38305141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.